Reversible cardiomyopathy associated with multicentric Castleman diseases: Successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody

International Journal of Hematology

Volumn 85, Issue 3, 2007, Pages 207-211

  Kanda, Junya ^a   Kawabata, Hiroshi ^a   Yamaji, Yuhei ^a   Ichinohe, Tatsuo ^a   Ishikawa, Takayuki ^a   Tamura, Toshihiro ^a   Furukawa, Yutaka ^a   Kimura, Takeshi ^a   Kita, Toru ^a   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Anti interleukin 6 receptor antibody; Heart failure; Multicentric Castleman disease

Indexed keywords

AMYLOID; ATLIZUMAB; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; FEMALE; HEART DILATATION; HEART DISEASE; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART VENTRICLE WALL MOTION; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MUSCLE HYPERTROPHY; PATHOGENESIS; PLASMA CELL;

ADULT; ANTIBODIES, MONOCLONAL; CARDIOMYOPATHIES; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INTERLEUKIN-6;

EID: 34247602631     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06186     Document Type: Article

References (26)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822-830.
2. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004;43:698-704.
3. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360-1367.
4. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627-2632.
5. Fukuchi M, Nozaki S, Fukushima J, et al. Multicentric Castleman disease associated with congestive heart failure [in Japanese]. Cardioangiology. 2003;54:251-256.
6. Yamamoto S, Nakatani S, Kijima K, et al. Multicentric Castleman's disease with reversible left ventricular diffuse hypokinesis [in Japanese ]. Nippon Naika Gakkai Zasshi. 2001;90:123-126.
7. Matsuo S, Nakamura Y, Nakae I, et al. Scintigraphic evaluation of ardiac metabolism in multicentric Castleman's disease. Intern Med. 2004;43:490-492.
8. Kingsmore SF, Silva OE, Hall BD, Sheldon EA, Cripe LD, St Clair EW. Presentation of multicentric Castleman's disease with sicca syndrome, cardiomyopathy, palmar and plantar rash. J Rheumatol. 1993;20:1588-1591.
9. Nishisato K, Nishino Y, Ohtomo T, et al. Multicentric Castleman's disease with heart failure: a case report [in Japanese]. Med J Asahikawa Red Cross Hospital. 2000;14:105-110.
10. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126:989-996.
11. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gpl30: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8:241-252.
12. Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 1993;260:1808-1810.
13. Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J. 2004;45:183-193.
14. Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail. 2001;3:415-421.
15. Janssen SP, Gayan-Ramirez G, Van den Bergh A, et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation. 2005;111:996-1005.
16. Kanda T, Nakajima T, Sakamoto H, Suzuki T, Murata K. An interleukin-6 secreting myxoma in a hypertrophic left ventricle. Chest. 1994;105:962-963.
17. Hirota H, Izumi M, Hamaguchi T, et al. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessels. 2004;19:237-241.
18. Ancey C, Menet E, Corbi P, et al. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc Res. 2003;59:78-85.
19. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin-6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 1995;92:4862-4866.
20. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
21. Yu X, Kennedy RH, Liu SJ. JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes. J Biol Chem. 2003;278:16304-16309.
22. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496-2506.
23. Araki T, Konno T, Soma R, et al. Crow-Fukase syndrome associated with high-output heart failure. Intern Med. 2002;41:638-641.
24. Ichikawa Y, Nakata T, Ohhata J, et al. Crow-Fukase syndrome with ischemic cardiomyopathy. Intern Med. 2001;40:726-730.
25. Bennett KR, Gu JW, Adair TH, Heath BJ. Elevated plasma concentration of vascular endothelial growth factor in cardiac myxoma. J Thorac Cardiovasc Surg. 2001;122:193-194.
26. Ohsugi Y, Tsuchimoto N. Pharmacological and clinical profile of humanized anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease [in Japanese]. Nippon Yakurigaku Zasshi. 2005;126:419-425.